Li Xianwu, Yang Hsueh-Ying, Giachelli Cecilia M
Department of Bioengineering, University of Washington, Seattle, WA 98195-5061, United States.
Atherosclerosis. 2008 Aug;199(2):271-7. doi: 10.1016/j.atherosclerosis.2007.11.031. Epub 2008 Jan 7.
Vascular calcification is associated with increased risk of cardiovascular events that are the most common cause of death in patients with end-stage renal disease. Clinical and experimental studies indicate that hyperphosphatemia is a risk factor for vascular calcification and cardiovascular mortality in these patients. Our previous studies demonstrated that phosphate transport through the type III sodium-dependent phosphate cotransporter, Pit-1, was necessary for phosphate-induced calcification and osteochondrogenic phenotypic change in cultured human smooth muscle cells (SMC). BMP-2 is a potent osteogenic protein required for osteoblast differentiation and bone formation that has been implicated in vascular calcification. In the present study, we have examined the effects of BMP-2 on human SMC calcification in vitro. We found that treatment of SMC with BMP-2 enhanced elevated phosphate-induced calcification, but did not induce calcification under normal phosphate conditions. mRNAs for BMP receptors, including ALK2, ALK3, ALK6, BMPR-II, ActR-IIA and ActR-IIB were all detected in human SMCs. Mechanistically, BMP-2 dose-dependently stimulated phosphate uptake in SMC (200 ng/ml BMP-2 vs. vehicle: 13.94 vs. 7.09 nmol/30 min/mg protein, respectively). Real-time PCR and Western blot revealed the upregulation of Pit-1 mRNA and protein levels, respectively, by BMP-2. More importantly, inhibition of phosphate uptake by a competitive inhibitor of sodium-dependent phosphate cotransport, phosphonoformic acid, abrogated BMP-2-induced calcification. These results indicate that phosphate transport via Pit-1 is crucial in BMP-2-regulated SMC calcification. In addition, BMP-2-induced Runx2 and inhibited SM22 expression, indicating that it promotes osteogenic phenotype transition in these cells. Thus, BMP-2 may promote vascular calcification via increased phosphate uptake and induction of osteogenic phenotype modulation in SMC.
血管钙化与心血管事件风险增加相关,而心血管事件是终末期肾病患者最常见的死亡原因。临床和实验研究表明,高磷血症是这些患者血管钙化和心血管死亡的危险因素。我们之前的研究表明,通过III型钠依赖性磷酸盐共转运体Pit-1进行的磷酸盐转运,对于磷酸盐诱导的培养人平滑肌细胞(SMC)钙化和骨软骨生成表型变化是必需的。骨形态发生蛋白-2(BMP-2)是成骨细胞分化和骨形成所需的一种强效成骨蛋白,与血管钙化有关。在本研究中,我们检测了BMP-2对人SMC体外钙化的影响。我们发现,用BMP-2处理SMC可增强高磷诱导的钙化,但在正常磷条件下不会诱导钙化。在人SMC中检测到了包括ALK2、ALK3、ALK6、BMPR-II、ActR-IIA和ActR-IIB在内的BMP受体的mRNA。从机制上讲,BMP-2剂量依赖性地刺激SMC摄取磷酸盐(200 ng/ml BMP-2与溶剂对照:分别为13.94与7.09 nmol/30分钟/毫克蛋白)。实时PCR和蛋白质印迹分别显示BMP-2上调了Pit-1 mRNA和蛋白水平。更重要的是,钠依赖性磷酸盐共转运的竞争性抑制剂膦甲酸抑制磷酸盐摄取,消除了BMP-2诱导的钙化。这些结果表明,通过Pit-1进行的磷酸盐转运在BMP-2调节的SMC钙化中至关重要。此外,BMP-2诱导Runx2表达并抑制SM22表达,表明它促进这些细胞的成骨表型转变。因此,BMP-2可能通过增加磷酸盐摄取和诱导SMC成骨表型调节来促进血管钙化。